ArticleBMC veterinary research2026
Baicalin alleviates Trueperella pyogenes-induced endometritis with associated changes in gut microbiota composition.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEndometritis is a prevalent reproductive disorder in livestock characterized by inflammation, oxidative stress, and microbial imbalance; however, the mechanistic links among these processes remain incompletely understood. This study investigated the protective effects of baicalin in a Trueperella pyogenes (T. pyogenes)-induced mouse model of endometritis by integrating network pharmacology, in vivo validation, and gut microbiota profiling.
resultsNetwork pharmacology analysis identified prostaglandin-endoperoxide synthase 2 (PTGS2, also known as cyclooxygenase-2, COX-2) and epidermal growth factor receptor (EGFR) as key targets of baicalin, with enrichment in arachidonic acid metabolism pathways. Baicalin treatment alleviated uterine pathology and suppressed inflammatory responses, as indicated by reduced tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and myeloperoxidase (MPO) activity. Baicalin also restored redox homeostasis by activating the Nrf2/Keap1/HO-1 pathway, increasing catalase (CAT) and superoxide dismutase (SOD) activities while decreasing malondialdehyde (MDA) levels, and concurrently reduced apoptosis, as evidenced by a lower ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2) (the Bax/Bcl-2 ratio). Concurrently, 16 S rRNA gene sequencing revealed that baicalin treatment was associated with alterations in gut microbiota composition, including changes in the relative abundance of several bacterial taxa linked to inflammation and metabolic functions. However, whether these microbial changes play a causal role in the observed protection remains to be determined.
conclusionsThese findings indicate that baicalin protects against endometritis through coordinated regulation of inflammation, oxidative stress, and apoptosis, and this protection was associated with shifts in gut microbiota composition. The results provide insight into the host-microbiota interactions accompanying endometritis and support baicalin as a potential therapeutic candidate, while highlighting the need for further causal investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.